Drug intelligence / Profile preview

remifentanil + ketamine

Development stage: Unknown
Lead developer: PharmaTher
Modality: Small Molecules
Administration: Intravenous

Overview

Remifentanil + ketamine is a drug combination used in anesthesia. This combination pairs remifentanil, a potent ultra short-acting synthetic opioid that acts as a μ-opioid receptor agonist, with ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist. The combination is particularly notable for its ability to attenuate remifentanil-induced hyperalgesia, which can occur with high-dose remifentanil administration. Ketamine helps reduce postoperative pain and morphine consumption when used alongside remifentanil-based anesthesia. The combination provides better hemodynamic stability compared to remifentanil alone or remifentanil with other agents.

Other names: remifentanil-ketamine combination

Targets

MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on remifentanil + ketamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on remifentanil + ketamine.

Explore the full profile